Here's What to Expect From Biogen's Next Earnings Report

Valued at a market cap of $18.9 billion, Biogen Inc. (BIIB) is a biotechnology company that discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The Cambridge, Massachusetts-based company is scheduled to announce its fiscal Q2 earnings for 2025 before the market opens on Thursday, Jul. 31.

Before this event, analysts project this biotech company to report a profit of $4.03 per share, down 23.7% from $5.28 per share in the year-ago quarter. The company has surpassed Wall Street’s bottom-line estimates in three of the last four quarters, while missing on another occasion. Its earnings of $3.02 per share in the previous quarter fell short of the consensus estimates by 7.4%.